… In recent years, there has been a growing repertoire of established UM cell lines derived
from primary and secondary patient tumours, or patient-derived xenografts (Table ​1). Most of …

… A precision oncology approach was feasible for patients with metastatic uveal melanoma,
with 60% receiving a therapy matched to identify molecular aberrations. The clinical benefit …

Uveal melanoma (UM) is the most common intraocular malignancy in adults. So far, no systemic
therapy or standard treatment exists to reduce the risk of metastasis and improve overall …

… ORR of both monotherapies and combinations (E–H): In vivo efficacy of VS4718 with Trametinib
or LXS196 in 3 uveal melanoma patient-derived xenografts. Overall response rate (ORR…

… of the mutational landscape in metastatic uveal melanoma is needed. … the role of liquid
biopsies in uveal melanoma in this review. … Finally, UM patient-derived xenograft models suggest …

… In vivo efficacy of ABT263 ± HDM201 in six uveal melanoma patient-derived xenografts. (A)
Overall response rate (ORR); the percentage in brackets correspond to an ORR lower than −…

… whereas the growth of xenografts established from B-Raf mutant melanoma cells was
unaffected [120]. A second recent study using subcutaneous UM tumor xenografts of Gα 11 Q209L …

Purpose: Dual-specificity phosphatase 4 (DUSP4) inactivates factors in the mitogen-activated
protein kinase (MAPK) signaling cascade, activated in uveal melanoma (UM) by mutations …

Aim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase
1/2) plus selumetinib (mitogen-activated extracellular signal-regulated kinase 1/2 inhibitor) …

… contribute to uveal melanoma growth and survival, clinical trials utilizing targeted therapy of
… Patient-derived xenograft (PDX) models are considered one of the more superior models to …